Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01308944 · ClinicalTrials.gov registry record · Phase 1
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
A Phase 1 study of Fallopian Tube Cancer and Primary Peritoneal Carcinoma, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01308944 is a Phase 1 study of Fallopian Tube Cancer and Primary Peritoneal Carcinoma that has completed, run by Washington University School of Medicine. The registered enrollment target is 24 participants, below the 256-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01308944, a Phase 1 study of Fallopian Tube Cancer and Primary Peritoneal Carcinoma, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is looking at the effect of biobehavioral factors such as stress and whether these factors alter how the body responds to chemotherapy, one of the purposes of this study is to determine if the addition of a beta-blocker such as Propranolol (Inderal) is tolerable when given with chemotherapy in the treatment of newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer. An additional purpose of the study is to understand if behavioral factors such as depression and anxiety can alter different blood markers that affect tumor vascularity. The Investigator wishes to determine whether the use of beta-blocker drugs such as Inderal, might alter these behavioral factors by drawing blood prior to and after the administration of Inderal as well as giving behavioral questionaires at different time points. Beta-blockers are commonly used for the treatment of hypertension, protection of the heart after a heart attack, and irregularities in heartbeats. Altering these factors might boost the immune system and affect other areas of cancer biology, thereby allowing the chemotherapy to be more effective. The significance of this research is that it may help improve our treatments of this disease in the future.
Conditions Studied
Interventions
- DRUG Propranolol
Study Locations (1)
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-08 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01308944
The ClinicalTrials.gov registry entry for NCT01308944 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 256-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 1 intervention - of which Propranolol is the first listed.
NCT01308944 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01308944 about?
NCT01308944 is a clinical study titled "Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients". This research is looking at the effect of biobehavioral factors such as stress and whether these factors alter how the body responds to chemotherapy, one of the purposes of this study is to determine if the addition of a beta-blocker such as Propranolol (Inderal) is tolerable when given with chemoth...
What is the current status of trial NCT01308944?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-08. Estimated completion is 2015-08.
What conditions does trial NCT01308944 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Invasive Epithelial Ovarian Cancer.
What interventions are being tested in trial NCT01308944?
The interventions under investigation include: Propranolol (DRUG).
Who is sponsoring clinical trial NCT01308944?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01308944 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 1
-
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
RECRUITING · Phase 1
-
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RECRUITING · Phase 1
-
A Study of ZN-c3 in Patients With Ovarian Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.